Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Piroxicam
Drug ID BADD_D01784
Description A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily.
Indications and Usage For treatment of osteoarthritis and rheumatoid arthritis.
Marketing Status approved; investigational
ATC Code M01AC01; M02AA07; S01BC06
DrugBank ID DB00554
KEGG ID D00127
MeSH ID D010894
PubChem ID 54676228
TTD Drug ID D00IBN
NDC Product Code 72789-211; 0093-0757; 71335-1999; 51927-1699; 70771-1429; 71335-2067; 72189-350; 22365-114; 59348-0014; 0093-0756; 29033-012; 42543-114; 71335-9622; 17337-0538; 38779-0302; 46438-0053; 49452-5476; 29300-255; 63629-9149; 0069-3220; 42291-674; 55700-697; 0069-3230; 62991-1113; 42291-677; 42571-177; 63629-9148; 71205-032; 72789-210; 59762-0145; 63629-9150; 53747-044; 60715-3270; 59762-0140; 64380-843; 70771-1430; 51927-0145; 60592-604; 63187-972; 64380-842; 71205-203; 46438-0639; 68981-041; 29033-013; 29300-256; 42543-115; 42571-176
UNII 13T4O6VMAM
Synonyms Piroxicam | CP-16171 | CP 16171 | CP16171 | Feldene
Chemical Information
Molecular Formula C15H13N3O4S
CAS Registry Number 36322-90-4
SMILES CN1C(=C(C2=CC=CC=C2S1(=O)=O)O)C(=O)NC3=CC=CC=N3
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Protein urine present13.13.02.006---
Haemorrhage24.07.01.002---
Weight abnormal13.15.01.016---
Purpura non-thrombocytopenic01.01.04.006---
Epidermal necrosis23.03.03.035---
Urine output increased13.13.03.002---
Antinuclear antibody positive13.06.01.003---
Hepatic enzyme increased13.03.04.028---
Adverse event08.06.01.0100.001064%-
Appetite disorder14.03.01.004; 19.09.01.002---
Inflammation08.01.05.007; 10.02.01.089---
Ischaemic stroke17.08.01.018; 24.04.06.0100.001064%-
Decreased appetite08.01.09.028; 14.03.01.005--
Ill-defined disorder08.01.03.049---
Abnormal sleep-related event17.15.02.007; 19.02.03.0090.001064%-
Pulmonary function test decreased13.19.01.001---
Renal impairment20.01.03.010---
Cystitis noninfective20.03.02.001--
Oral mucosa erosion07.05.06.0090.001064%-
Injection site injury08.02.03.046; 12.07.03.0460.001064%-
Liver injury09.01.07.022; 12.01.17.0120.001595%-
Cholestatic liver injury09.01.07.0160.001064%-
Drug-induced liver injury09.01.07.023; 12.03.01.0440.001595%-
Drug reaction with eosinophilia and systemic symptoms10.01.01.021; 12.03.01.064; 23.03.05.0050.002127%-
Perforation08.01.03.058---
Penile ulceration21.12.01.019; 23.07.03.0200.001064%-
Lip erosion07.05.06.0110.001064%-
Embolia cutis medicamentosa08.02.03.052; 12.07.03.052; 24.01.01.0300.001064%-
Hyperlipasaemia14.11.01.0230.001595%-
Cholestatic pruritus09.01.05.012; 23.03.12.0120.001064%-
The 8th Page    First    Pre   8 9    Next   Last    Total 9 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene